Literature DB >> 22969842

Increased Sox2 copy number in lung squamous cell carcinomas.

Hidefumi Sasaki1, Keisuke Yokota, Yu Hikosaka, Satoru Moriyama, Motoki Yano, Yoshitaka Fujii.   

Abstract

The transcription factor Sox2 is necessary for foregut morphogenesis. Sox2 is also required for the normal development of the trachea and lung. Recently, Sox2 amplifications were investigated using large-scale single nucleotide polymorphism arrays in esophageal and lung cancer. We hypothesized that Sox2 overexpression might be correlated with clinicopathological features of lung cancers. The increased copy number of the Sox2 gene was analyzed by real-time polymerase chain reaction amplifications in 127 surgically treated non-small cell lung cancer cases from Nagoya City University Hospital, Japan. A total of 87 squamous cell carcinoma (SCC) cases were involved. An increased Sox2 gene copy number was found in 42 (33.1%) lung cancer patients. Increased Sox2 copy number status was significantly correlated with gender (females, 9.5% vs. males, 34.1%; p=0.0026), smoking status (never smoker, 4.8% vs. smoker, 32.9%; p=0.0003) and pathological subtypes (squamous cell carcinoma, 44.8% vs. non-squamous cell carcinoma, 7.5%; p<0.0001). However, among the SCCs, the Sox2 copy number status was not significantly correlated with gender, smoking status, pathological stage or differentiation status. An increased Sox2 copy number is common within SCC.

Entities:  

Year:  2011        PMID: 22969842      PMCID: PMC3438854          DOI: 10.3892/etm.2011.374

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  28 in total

1.  Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation.

Authors:  Cristina Gontan; Anne de Munck; Marcel Vermeij; Frank Grosveld; Dick Tibboel; Robbert Rottier
Journal:  Dev Biol       Date:  2008-02-29       Impact factor: 3.582

2.  Thoracic and cardiovascular surgery in Japan during 2007. Annual report by the Japanese Association for Thoracic Surgery.

Authors:  Yuichi Ueda; Yoshitaka Fujii; Hiroyuki Kuwano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09

Review 3.  Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors:  P E Postmus
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

4.  EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.

Authors:  Hidefumi Sasaki; Katsuhiko Endo; Akimitsu Konishi; Minoru Takada; Masaaki Kawahara; Keiji Iuchi; Akihide Matsumura; Meinoshin Okumura; Hisaichi Tanaka; Tomoya Kawaguchi; Toshiki Shimizu; Hiroshi Takeuchi; Motoki Yano; Ichiro Fukai; Yoshitaka Fujii
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 5.  HMG domain proteins: architectural elements in the assembly of nucleoprotein structures.

Authors:  R Grosschedl; K Giese; J Pagel
Journal:  Trends Genet       Date:  1994-03       Impact factor: 11.639

6.  Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas.

Authors:  Lynette M Sholl; Kevin B Long; Jason L Hornick
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-01

7.  Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.

Authors:  Katsuhiko Endo; Akimitsu Konishi; Hidefumi Sasaki; Minoru Takada; Hisaichi Tanaka; Meinoshin Okumura; Masaaki Kawahara; Hironori Sugiura; Yoshiyuki Kuwabara; Ichiro Fukai; Akihide Matsumura; Motoki Yano; Yoshihiro Kobayashi; Kotaro Mizuno; Hiroshi Haneda; Eriko Suzuki; Keiji Iuchi; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2005-09-30       Impact factor: 5.705

8.  Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

Authors:  Katsuhiko Endo; Hidefumi Sasaki; Motoki Yano; Yoshihiro Kobayashi; Haruhiro Yukiue; Hiroshi Haneda; Eriko Suzuki; Osamu Kawano; Yoshitaka Fujii
Journal:  Oncol Rep       Date:  2006-09       Impact factor: 3.906

Review 9.  Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors.

Authors:  Véronique Lefebvre; Bogdan Dumitriu; Alfredo Penzo-Méndez; Yu Han; Bhattaram Pallavi
Journal:  Int J Biochem Cell Biol       Date:  2007-06-06       Impact factor: 5.085

10.  The Dichaete gene of Drosophila melanogaster encodes a SOX-domain protein required for embryonic segmentation.

Authors:  S R Russell; N Sanchez-Soriano; C R Wright; M Ashburner
Journal:  Development       Date:  1996-11       Impact factor: 6.868

View more
  11 in total

1.  Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer.

Authors:  Yanfeng Wu; Xiao Du; Chengjun Xue; Detao Li; Qian Zheng; Xue Li; Hui Chen
Journal:  Med Oncol       Date:  2013-10-15       Impact factor: 3.064

2.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

Review 3.  The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Niki Karachaliou; Rafael Rosell; Santiago Viteri
Journal:  Transl Lung Cancer Res       Date:  2013-06

4.  The role of SOX-2 on the survival of patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

5.  The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis.

Authors:  Yansu Chen; Yefei Huang; Yulin Huang; Junjie Chen; Shouyu Wang; Jianwei Zhou
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

6.  Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.

Authors:  Johanna Samulin Erdem; Vidar Skaug; Per Bakke; Amund Gulsvik; Aage Haugen; Shanbeh Zienolddiny
Journal:  BMC Cancer       Date:  2016-01-19       Impact factor: 4.430

7.  The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer.

Authors:  Eva Sodja; Matija Rijavec; Ana Koren; Aleksander Sadikov; Peter Korošec; Tanja Cufer
Journal:  Radiol Oncol       Date:  2016-04-23       Impact factor: 2.991

Review 8.  Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Qingbao Li; Fang Liu; Yuan Zhang; Lei Fu; Cong Wang; Xuan Chen; Shanghui Guan; Xiangjiao Meng
Journal:  Oncotarget       Date:  2016-06-07

9.  Expression and significance of SOX2 in non-small cell lung carcinoma.

Authors:  Jie Ying; Chao Shi; Chuan-Sheng Li; Li-Ping Hu; Wei-Dong Zhang
Journal:  Oncol Lett       Date:  2016-08-30       Impact factor: 2.967

10.  SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas.

Authors:  Shanbo Zheng; Yunjian Pan; Rui Wang; Yuan Li; Chao Cheng; Xuxia Shen; Bin Li; Difan Zheng; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2015-10-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.